莱美药业：关于部分产品拟中选国家集采药品接续采购的公告

Core Viewpoint - Laimei Pharmaceutical announced participation in the national centralized procurement for drugs whose agreements have expired, with some products expected to be selected in the upcoming procurement process [1] Group 1: Company Announcement - Laimei Pharmaceutical and its wholly-owned subsidiary, Hunan Kangyuan Pharmaceutical Co., Ltd., participated in the bidding organized by the National Centralized Procurement Office for drugs whose agreements have expired [1] - The National Centralized Procurement Office published the proposed selection results on February 10, 2026, indicating that some products from Laimei Pharmaceutical and Hunan Kangyuan are expected to be selected [1]